Introducing
Prezi AI.
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Loading…
Nintedanib in progressive fibrosing interstitial lung diseases
2
Transcript
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
José Andrés Jara Escobar
Definitions
- Nintedanib is an intracellular inhibitor of tyrosine kinases, it inhibits processes involved in the progression of lung fibrosis.
- Pulmonary fibrosis is a chronic and progressive lung disease where the air sacs in the lungs, called the alveoli, become scarred and stiff, making it difficult to breathe and get enough oxygen into the bloodstream.
Applications in Medicine
Its important to know about the symptoms, signs and the new treatments for this disease.
In case of nintedanib the efficacy of this drug has been shown in idiopathic pulmonary fibrosis
Applications in Medicine
Pros and Cons
Pros:
- In the overall population, the adjusted rate of decline in the FVC was −80.8 ml per year with nintedanib and −187.8 ml per year with placebo, for a between-group difference of 107.0 ml per year
Cons:
- Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its efficacy across a broad range of fibrosing lung diseases is unknown.
Pros and Cons
Issue Applied in Ecuador
In Ecuador its important to know about this disease, how to diagnose it and what are the multiple treatments for this disease
Issue applied in Ecuador
Conclusion
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event.
Choose a template
Presentations from around the world
Learn more about creating dynamic, engaging presentations with Prezi